The economic evaluation of personalised oncology medicines: ethical challenges

被引：15
作者：
Lewis, Jan R. R. [1 ]
Lipworth, Wendy L. [2 ]
Kerridge, Ian H. [1 ]
Day, Richard O. [3 ]
机构：
[1] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW 2006, Australia
[2] Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW, Australia
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
来源：
MEDICAL JOURNAL OF AUSTRALIA | 2013年 / 199卷 / 07期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; EGFR MUTATION; CARBOPLATIN-PACLITAXEL; OPEN-LABEL; GEFITINIB; SURVIVAL; TRIAL; CHEMOTHERAPY; MULTICENTER;
D O I：
10.5694/mja13.10046
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Insights into the molecular drivers of cancer are providing opportunities for the development of new targeted treatments and more personalised approaches to cancer management Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell Lung cancer (NSCLC). First-line access to these newer treatments remains unfunded after several considerations by the Pharmaceutical Benefits Advisory Committee and their assessment that these are not cost-effective treatments. We suggest that there may be evidentiary and ethical challenges associated with the assessment of the cost-effectiveness of personalised oncology medicines in Australia, and that a new approach is needed to determine the value and cost-effectiveness of personalised medicine.
引用
收藏
页码：471 / 473
页数：3
相关论文
共 24 条
  • [11] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) : 2380 - 2388
  • [12] Assessing Personalized Medicines in Australia: A National Framework for Reviewing Codependent Technologies
    Merlin, Tracy
    Farah, Claude
    Schubert, Camille
    Mitchell, Andrew
    Hiller, Janet E.
    Ryan, Philip
    [J]. MEDICAL DECISION MAKING, 2013, 33 (03) : 333 - 342
  • [13] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi, Tetsuya
    Morita, Satoshi
    Yatabe, Yasushi
    Negoro, Shunichi
    Okamoto, Isamu
    Tsurutani, Junji
    Seto, Takashi
    Satouchi, Miyako
    Tada, Hirohito
    Hirashima, Tomonori
    Asami, Kazuhiro
    Katakami, Nobuyuki
    Takada, Minoru
    Yoshioka, Hiroshige
    Shibata, Kazuhiko
    Kudoh, Shinzoh
    Shimizu, Eiji
    Saito, Hiroshi
    Toyooka, Shinichi
    Nakagawa, Kazuhiko
    Fukuoka, Masahiro
    [J]. LANCET ONCOLOGY, 2010, 11 (02) : 121 - 128
  • [14] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
    Mok, Tony S.
    Wu, Yi-Long
    Thongprasert, Sumitra
    Yang, Chih-Hsin
    Chu, Da-Tong
    Saijo, Nagahiro
    Sunpaweravong, Patrapim
    Han, Baohui
    Margono, Benjamin
    Ichinose, Yukito
    Nishiwaki, Yutaka
    Ohe, Yuichiro
    Yang, Jin-Ji
    Chewaskulyong, Busyamas
    Jiang, Haiyi
    Duffield, Emma L.
    Watkins, Claire L.
    Armour, Alison A.
    Fukuoka, Masahiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957
  • [15] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
    Ohashi, Kadoaki
    Maruvka, Yosef E.
    Michor, Franziska
    Pao, William
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1070 - 1080
  • [16] Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?
    Rimawi, Mothaffar
    Hilsenbeck, Susan G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 453 - 458
  • [17] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, Rafael
    Carcereny, Enric
    Gervais, Radj
    Vergnenegre, Alain
    Massuti, Bartomeu
    Felip, Enriqueta
    Palmero, Ramon
    Garcia-Gomez, Ramon
    Pallares, Cinta
    Miguel Sanchez, Jose
    Porta, Rut
    Cobo, Manuel
    Garrido, Pilar
    Longo, Flavia
    Moran, Teresa
    Insa, Amelia
    De Marinis, Filippo
    Corre, Romain
    Bover, Isabel
    Illiano, Alfonso
    Dansin, Eric
    de Castro, Javier
    Milella, Michele
    Reguart, Noemi
    Altavilla, Giuseppe
    Jimenez, Ulpiano
    Provencio, Mariano
    Angel Moreno, Miguel
    Terrasa, Josefa
    Munoz-Langa, Jose
    Valdivia, Javier
    Isla, Dolores
    Domine, Manuel
    Molinier, Olivier
    Mazieres, Julien
    Baize, Nathalie
    Garcia-Campelo, Rosario
    Robinet, Gilles
    Rodriguez-Abreu, Delvys
    Lopez-Vivanco, Guillermo
    Gebbia, Vittorio
    Ferrera-Delgado, Lioba
    Bombaron, Pierre
    Bernabe, Reyes
    Bearz, Alessandra
    Artal, Angel
    Cortesi, Enrico
    Rolfo, Christian
    Sanchez-Ronco, Maria
    Drozdowskyj, Ana
    [J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246
  • [18] Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy
    Shepherd, FA
    Tsao, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1219 - 1220
  • [19] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 123 - 132
  • [20] EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
    Takano, Toshimi
    Fukui, Tomoya
    Ohe, Yuichiro
    Tsuta, Koji
    Yamamoto, Seiichiro
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Furuta, Koh
    Tamura, Tomohide
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5589 - 5595
123